CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 48 enrolled
Drug / intervention
Bevacizumab +1 moredrug
Likely dose
Bevacizumab 10mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00407563
NCT00407563Phase 2Completed
CompareCT.gov

A Phase 2 Study of Bevacizumab With Abraxane in Patients With Recurrent, Platinum-Resistant Primary Epithelial Ovarian or Primary Peritoneal Carcinoma

Accelerated Community Oncology Research Network·interventional·Posted Dec 5, 2006·Updated Apr 5, 2012

In Brief

A Phase 2 clinical trial evaluating Bevacizumab and Abraxane for Epithelial Ovarian Cancer and Primary Peritoneal Carcinoma. Completed, enrolled 48 participants across 11 sites.

Detailed Summary

The purpose of this study is to evaluate the effectiveness and tolerability of the combination of bevacizumab and Abraxane in the treatment of women with epithelial ovarian cancer or peritoneal cancer. The study will also evaluate how the patient's quality of life is during their treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpithelial Ovarian Cancer, Primary Peritoneal Carcinoma
CountriesUnited States
CollaboratorsGenentech, Inc., Celgene Corporation

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 5, 2006
Enrollment StartJan 1, 2007
Primary CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 19.6 years ago

Interventions

Bevacizumabdrug

Bevacizumab will be given via IV infusion at 10mg/kg given on days 1 and 15 of a 28-day cycle.

Abraxanedrug

Abraxane will be given via IV infusion at 100mg/m²over 30 minutes on days 1, 8, and 15 of a 28-day cycle.